mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and central nervous system drugs. the company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. the company's specialty brands segment includes branded medicines; its specialty generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the global medical imaging segment includes contrast media and nuclear imaging agents. to learn more about mallinckrodt, visit
Company profile
Ticker
MNKTQ, MNKTQ
Exchange
Website
CEO
Mark Trudeau
Employees
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Acthar IP Unlimited Company • Cache Holdings Limited • Carnforth Limited • Dritte CORSA Verwaltungsgesellschaft GmbH • Ikaria Australia Pty Ltd • Ikaria Canada Inc. • IMC Exploration Company • Infacare Pharmaceutical Corporation • INO Therapeutics LLC • Ludlow LLC ...
IRS number
981088325
MNKTQ stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
15 Apr 24
DEF 14A
Definitive proxy
15 Apr 24
8-K
Regulation FD Disclosure
8 Apr 24
8-K
Changes in Registrant's Certifying Accountant
8 Apr 24
10-K
2023 FY
Annual report
26 Mar 24
8-K
Mallinckrodt plc Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides 2024 Guidance
26 Mar 24
8-K
Regulation FD Disclosure
20 Mar 24
8-K
Departure of Directors or Certain Officers
2 Feb 24
8-K
Departure of Directors or Certain Officers
26 Jan 24
8-K
Cost Associated with Exit or Disposal Activities
9 Jan 24
Transcripts
MNKTQ
Earnings call transcript
2022 Q3
8 Nov 22
MNKTQ
Earnings call transcript
2022 Q2
11 Aug 22
MNKTQ
Earnings call transcript
2020 Q2
4 Aug 20
MNKTQ
Earnings call transcript
2020 Q1
5 May 20
MNKTQ
Earnings call transcript
2019 Q4
25 Feb 20
MNKTQ
Earnings call transcript
2019 Q3
5 Nov 19
MNKTQ
Earnings call transcript
2019 Q2
6 Aug 19
MNKTQ
Earnings call transcript
2019 Q1
7 May 19
MNKTQ
Earnings call transcript
2018 Q4
26 Feb 19
MNKTQ
Earnings call transcript
2018 Q3
6 Nov 18
Latest ownership filings
SC 13D/A
Hein Park Capital Management LP
8 Apr 24
SC 13D/A
Squarepoint Ops LLC
15 Mar 24
4
Steven A. Tananbaum
12 Mar 24
3
Hugh Paul ONeill
11 Mar 24
SC 13D/A
Hein Park Capital Management LP
11 Mar 24
4
Steven A. Tananbaum
20 Feb 24
4
Jon Zinman
20 Feb 24
4
Wesley Wheeler
20 Feb 24
4
David J. Stetson
20 Feb 24
4
Abbas Hussain
20 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 452.00 mm | 452.00 mm | 452.00 mm | 452.00 mm | 452.00 mm | 452.00 mm |
Cash burn (monthly) | 28.97 mm | 3.60 mm | 571.37 mm | 206.72 mm | 139.57 mm | 22.49 mm |
Cash used (since last report) | 198.69 mm | 24.69 mm | 3.92 bn | 1.42 bn | 957.33 mm | 154.28 mm |
Cash remaining | 253.31 mm | 427.31 mm | -3.47 bn | -965.94 mm | -505.33 mm | 297.72 mm |
Runway (months of cash) | 8.7 | 118.7 | -6.1 | -4.7 | -3.6 | 13.2 |
Institutional ownership, Q3 2023
30.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 5 |
Opened positions | 1 |
Closed positions | 31 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 8.00 mm |
Total shares | 3.98 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Bracebridge Capital | 2.03 mm | $967.00 k |
Millstreet Capital Management | 1.04 mm | $0.00 |
Continental General Insurance | 880.82 k | $5.55 mm |
XTX Topco | 17.34 k | $1.48 mm |
Acadian Asset Management | 10.21 k | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Mar 24 | Goldentree Asset Management | Ordinary Shares | Buy | Acquire P | Yes | No | 43.625 | 83,000 | 3.62 mm | 2,399,035 |
2 Feb 24 | Jason Daniel Goodson | RSU Ordinary Shares | Grant | Dispose A | No | No | 0 | 16,413 | 0.00 | 16,413 |
2 Feb 24 | Peter C Richardson | RSU Ordinary Shares | Grant | Dispose A | No | No | 0 | 10,258 | 0.00 | 10,258 |
2 Feb 24 | Bryan M. Reasons | RSU Ordinary Shares | Grant | Dispose A | No | No | 0 | 20,517 | 0.00 | 20,517 |